期刊文献+

尤特奇L30D-55在肠溶制剂中的工艺研究 被引量:1

Study on the Technology of Eugratid L30D-55 in Enteric-coated Preparations
下载PDF
导出
摘要 目的对尤特奇L30D-55理化性质进行测定,对其在肠溶制剂上的应用提供合理的依据。方法采用差示热扫描测定其玻璃化温度(Tg),考察增塑剂对玻璃化温度及最低成膜温度的影响。以双氯芬酸钠作为药物模型,通过体外释放实验考察尤特奇L30D-55肠溶制剂的性能。结果 L30D-55在应用时其Tg、最低成膜温度的变化是主要监测点,并可以通过增塑剂的加入调整二者的变化。其水分散体和有机溶剂包衣成膜原理不同。在生产中片床温度、固含量设定及配制包衣时的设备参数设定不当均会导致包衣质量不合格。结论通过对尤特奇L30D-55物理性质的测定,为肠溶制剂制备中各项参数的设定提供依据。 OBJECTIVE To determine the physicochemical properties of Eugradit L30D-55 and provide a reasonable basis for its application in enteric agents. METHODS The glass transition temperature was measured by differential scanning and the effect of plasticizer on the glass transition temperature and minimum film formation temperature was investigated.To investigate the characteristics of Eugradit L30D-55 enteric-coated formulations,a vitro release test was design while diclofenac sodium as a drug model. RESULTS The L30D-55 was the main monitoring point for its Tg and minimum film formation temperature when applied,and the change of both could be adjusted by the addition of plasticizer.Its aqueous dispersion and organic solvent coating film of its different principles.In the production of bed temperature,the solid content setting and configuration of the equipment parameters are not properly set the coating quality will lead to unqualified. CONCLUSION The determination of the physical properties of Eugradit L30D-55 provides a basis for the setting of various parameters in the preparation of enteric agents.
作者 金凯 周立宏 董玉洁 JIN Kai;ZHOU Li-hong;DONG Yu-jie(Yantai Luyin Pharmaceutical Co.Ltd,Yantai 264001,China)
出处 《海峡药学》 2019年第2期24-26,共3页 Strait Pharmaceutical Journal
关键词 丙烯酸树脂 尤特奇L30D-55 口服固体制剂 工艺参数 Acrylic resin Eugradit L30D-55 Oral solid preparation Process parameters
  • 相关文献

参考文献3

二级参考文献50

  • 1崔宝国,李林军,黄桂华.丙烯酸树脂在微丸包衣中的应用[J].齐鲁药事,2006,25(10):614-616. 被引量:10
  • 2吴君华,柳晨,张瑜,朱赛杰,姜嫣嫣,裴元英.致孔剂调节布地奈德肠溶缓释微丸释放速率的研究[J].中国药学杂志,2007,42(17):1325-1329. 被引量:9
  • 3DING J S, YAN J. Application of latex/false glue watercoating technologies in pharmaceutics [J].华西药学杂志,2003,18(5): 349-352.
  • 4DASHEVSKY A, MOHAMAD A. Development of pulsatilemultiparticulate drug delivery system coated with aqueousdispersion aquacoat ECD [J]. Int J Pharm, 2006,318(1):124-131.
  • 5MEKA L, KESAVAN B, CHINNALA K M, et al. Preparationof a matrix type multiple-unit gastro retentive floating drugdelivery system for captopril based on gas formation technique:in vitro evaluation [J]. AAPS PharmSciTech, 2008, 9(2):612-619.
  • 6BODMEIER R, PAERATAKUL O. Process and formulationvariables affecting the drug release from chlorpheniraminemaleate-loaded beads coated with commercial andself-prepared aqueous ethyl cellulose pseudolatexes [J]. Int JPharm, 1991,70(1): 59-68.
  • 7ANDREAZZA I F, FERRAZ H G. Preparation of pelletscontaining highly soluble drug by extrusion/spheronisation andcoating with Kollicoat? SR30D [J]. Braz Arch Biol Technol,2011,54(2):315-320.
  • 8IYER U, HONG W, DAS N, et al. Comparative evaluation ofthree organic solvent and dispersion-based ethylcellulosecoating formulations [J]. Pharm Technol, 1990, 14(9): 68-86.
  • 9Nollenberger K, Albers J. Poly (meth) acrylate-based coatings [J]. Int JPharm, 2013, 457 (2) : 461-469.
  • 10Petereit HU, Weisbrod W. Formulation and process considerations affecting the stability of solid dosage forms formulated with methacrylate copolymers [J]. Eur J Pharm Biopharm, 1999, 47(1): 15-25.

共引文献8

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部